As More Indian Companies Dive Into Biosimilars, Will Success In Generic Drugs Repeat?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In August, when leading Indian drug maker Dr. Reddy's Labs launched Cresp, a biosimilar brand of Amgen's darbepoetin alfa Aranesp, G.V.Prasad, Reddy's chief executive officer exulted at a media briefing that his company may well be on course to becoming the largest biologics player in the world in a few years, next only to Swiss giant Roche
You may also be interested in...
Business News, In Brief
Pfizer Lays Out Primary Care Business Development Opportunities
Business News, In Brief
Pfizer Lays Out Primary Care Business Development Opportunities
With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market
MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro